Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.83 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445885 | 0.93 | ALDH1A1 (0.97) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| SCHEMBL14726057 | 0.91 | ALDH1A1 (1.00) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16370438 | 0.91 | ALDH1A1 (0.94) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29388956 | 0.90 | ALDH1A1 (0.97) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| SCHEMBL1019655 | 0.87 | ALDH1A1 (0.63) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| SCHEMBL25368316 | 0.86 | POLB (0.73) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| SCHEMBL15347670 | 0.86 | POLB (0.73) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| SCHEMBL11549718 | 0.84 | POLB (0.71) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| SCHEMBL11556051 | 0.84 | POLB (0.71) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 | |
| SCHEMBL11551844 | 0.84 | POLB (0.71) | LMNAALDH1A1KCNJ1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097413-B1 | 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-8604029-B2 | 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD BRITISH BODY CORPORATE (GB) | 2013-12-10 | — | — | US | disclosed |
| CN-101679410-B | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD | 2013-11-27 | — | — | CN | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| CN-102105170-A | Antifungal combination therapy | F2G LTD | 2011-06-22 | — | — | CN | disclosed |
| EP-2303329-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| CN-101679410-A | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD | 2010-03-24 | — | — | CN | disclosed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
| WO-2009144473-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
| EP-2097413-A1 | 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G Limited (GB) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008062182-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | LMNA 3870/4885ALDH1A1 2813/4885KCNJ1 540/4885 |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | LMNA 1805/4885ALDH1A1 318/4885KCNJ1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.